Top

Published in:

Open Access 01-05-2021 | Insulins | Review

New closed-loop insulin systems

Authors: Charlotte K. Boughton, Roman Hovorka

Published in: Diabetologia | Issue 5/2021

Abstract

Advances in diabetes technologies have enabled the development of automated closed-loop insulin delivery systems. Several hybrid closed-loop systems have been commercialised, reflecting rapid transition of this evolving technology from research into clinical practice, where it is gradually transforming the management of type 1 diabetes in children and adults. In this review we consider the supporting evidence in terms of glucose control and quality of life for presently available closed-loop systems and those in development, including dual-hormone closed-loop systems. We also comment on alternative ‘do-it-yourself’ closed-loop systems. We remark on issues associated with clinical adoption of these approaches, including training provision, and consider limitations of presently available closed-loop systems and areas for future enhancements to further improve outcomes and reduce the burden of diabetes management.

Graphical abstract

Available only for authorised users

Bergenstal RM, Klonoff DC, Garg SK et al (2013) Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 369(3):224–232. https://doi.org/10.1056/NEJMoa1303576CrossRefPubMed

Forlenza GP, Li Z, Buckingham BA et al (2018) Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care 41(10):2155–2161. https://doi.org/10.2337/dc18-0771CrossRefPubMed

Battelino T, Nimri R, Dovc K, Phillip M, Bratina N (2017) Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: A randomized controlled trial. Diabetes Care 40(6):764–770. https://doi.org/10.2337/dc16-2584CrossRefPubMed

El Youssef J, Castle J, Ward WK (2009) A review of closed-loop algorithms for glycemic control in the treatment of type 1 diabetes. Algorithms 2(1):518–532. https://doi.org/10.3390/a2010518

Bergenstal R, Garg S, Weinzimer SA et al (2016) Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316(13):1407–1408. https://doi.org/10.1001/jama.2016.11708CrossRefPubMed

Bekiari E, Kitsios K, Thabit H et al (2018) Artificial pancreas treatment for outpatients with type 1 diabetes: Systematic review and meta-analysis. BMJ 361. https://doi.org/10.1136/bmj.k1310

Karageorgiou V, Papaioannou TG, Bellos I et al (2019) Effectiveness of artificial pancreas in the non-adult population: A systematic review and network meta-analysis. Metabolism 90:20–30. https://doi.org/10.1016/j.metabol.2018.10.002

Farrington C (2018) Psychosocial impacts of hybrid closed-loop systems in the management of diabetes: A review. Diabet Med 35(4):436–449. https://doi.org/10.1111/dme.13567CrossRefPubMed

Garg SK, Weinzimer SA, Tamborlane WV et al (2017) Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 19(3):155–163. https://doi.org/10.1089/dia.2016.0421CrossRefPubMedPubMedCentral

10.

Forlenza GP, Pinhas-Hamiel O, Liljenquist DR et al (2019) Safety evaluation of the MiniMed 670G system in children 7-13 years of age with type 1 diabetes. Diabetes Technol Ther 21(1):11–19. https://doi.org/10.1089/dia.2018.0264CrossRefPubMedPubMedCentral

11.

Bergenstal RM, Nimri R, Beck RW et al (2021) A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 397(10270):208–219. https://doi.org/10.1016/S0140-6736(20)32514-9

12.

Brown SA, Kovatchev BP, Raghinaru D et al (2019) Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 381(18):1707–1717. https://doi.org/10.1056/NEJMoa1907863CrossRefPubMedPubMedCentral

13.

Breton MD, Kanapka LG, Beck RW et al (2020) A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med 383(9):836–845. https://doi.org/10.1056/NEJMoa2004736CrossRefPubMedPubMedCentral

14.

Stewart ZA, Wilinska ME, Hartnell S et al (2016) Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med 375(7):644–654. https://doi.org/10.1056/NEJMoa1602494CrossRefPubMed

15.

Thabit H, Tauschmann M, Allen JM et al (2015) Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 373(22):2129–2140. https://doi.org/10.1056/NEJMoa1509351CrossRefPubMedPubMedCentral

16.

Tauschmann M, Thabit H, Bally L et al (2018) Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: A multicentre, 12-week randomised trial. Lancet 392(10155):1321–1329. https://doi.org/10.1016/S0140-6736(18)31947-0

17.

Tauschmann M, Allen JM, Nagl K et al (2019) Home use of day-and-night hybrid closed-loop insulin delivery in very young children: A multicenter, 3-week, randomized trial. Diabetes Care 42(4):594–600. https://doi.org/10.2337/dc18-1881CrossRefPubMed

18.

Benhamou PY, Franc S, Reznik Y et al (2019) Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: A 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digital Health 1(1):E17–E25CrossRef

19.

Lewis D, Leibrand S (2016) Real-world use of open source artificial pancreas systems. J Diabetes Sci Technol 10(6):1411. https://doi.org/10.1177/1932296816665635CrossRefPubMedPubMedCentral

20.

El-Khatib FH, Balliro C, Hillard MA et al (2017) Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: A multicentre randomised crossover trial. Lancet 389(10067):369–380. https://doi.org/10.1016/S0140-6736(16)32567-3

21.

Russell SJ, El-Khatib FH, Sinha M et al (2014) Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 371(4):313–325. https://doi.org/10.1056/NEJMoa1314474CrossRefPubMedPubMedCentral

22.

Haidar A, Messier V, Legault L, Ladouceur M, Rabasa-Lhoret R (2017) Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial. Diabetes Obes Metab 19(5):713–720. https://doi.org/10.1111/dom.12880CrossRefPubMed

23.

Levetan C, Want LL, Weyer C et al (2003) Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 26(1):1–8. https://doi.org/10.2337/diacare.26.1.1CrossRefPubMed

24.

Haidar A, Tsoukas MA, Bernier-Twardy S et al (2020) A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: A randomized controlled crossover trial. Diabetes Care 43(3):597–606. https://doi.org/10.2337/dc19-1922CrossRefPubMed

25.

Berget C, Thomas SE, Messer LH et al (2020) A clinical training program for hybrid closed loop therapy in a pediatric diabetes clinic. J Diabetes Sci Technol 14(2):290–296. https://doi.org/10.1177/1932296819835183CrossRefPubMed

26.

Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM (2019) One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care 42(12):2190–2196. https://doi.org/10.2337/dc19-0855CrossRefPubMedPubMedCentral

27.

Messer LH, Berget C, Vigers T et al (2020) Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatr Diabetes 21(2):319–327CrossRef

28.

Duffus SH, Ta'ani ZA, Slaughter JC, Niswender KD, Gregory JM (2020) Increased proportion of time in hybrid closed-loop "auto mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump. Diabetes Obes Metab 22(4):688–693. https://doi.org/10.1111/dom.13912CrossRefPubMed

29.

Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV (2008) Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31(5):934–939. https://doi.org/10.2337/dc07-1967CrossRefPubMed

30.

Gingras V, Rabasa-Lhoret R, Messier V, Ladouceur M, Legault L, Haidar A (2016) Efficacy of dual-hormone artificial pancreas to alleviate the carbohydrate-counting burden of type 1 diabetes: A randomized crossover trial. Diabetes Metab 42(1):47–54. https://doi.org/10.1016/j.diabet.2015.05.001CrossRefPubMed

31.

Riddell MC, Zaharieva DP, Yavelberg L, Cinar A, Jamnik VK (2015) Exercise and the development of the artificial pancreas: One of the more difficult series of hurdles. J Diabetes Sci Technol 9(6):1217–1226. https://doi.org/10.1177/1932296815609370CrossRefPubMedPubMedCentral

32.

Tagougui S, Taleb N, Legault L et al (2020) A single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type 1 diabetes: Announced (with or without bolus reduction) vs unannounced exercise strategies. Diabetologia 63(11):2282–2291. https://doi.org/10.1007/s00125-020-05244-y

33.

Quintal A, Messier V, Rabasa-Lhoret R, Racine E (2019) A critical review and analysis of ethical issues associated with the artificial pancreas. Diabetes Metab 45(1):1–10. https://doi.org/10.1016/j.diabet.2018.04.003CrossRefPubMed

34.

Hsu LJ, Buckingham BA, Basina M et al (2020) Fast-acting insulin aspart use with the MiniMed™ 670G system. Diabetes Technol Ther. https://doi.org/10.1089/dia.2020.0083

35.

Bode BW, Carlson AL, Liu R et al (2020) 233-OR: Ultra-Rapid Lispro (URLi) demonstrates similar time-in-target range to Humalog with the Medtronic Minimed 670G hybrid closed-loop system. Diabetes 69(Supplement 1):233-OR (Abstract). https://doi.org/10.1093/jalm/jfaa220CrossRef

36.

Hovorka R (2011) Closed-loop insulin delivery: From bench to clinical practice. Nat Rev Endocrinol 7(7):385–395. https://doi.org/10.1038/nrendo.2011.32CrossRefPubMed

Title: New closed-loop insulin systems
Authors: Charlotte K. Boughton
Roman Hovorka
Publication date: 01-05-2021
Publisher: Springer Berlin Heidelberg
Keywords: Insulins
Hypoglycemia
Insulins
Type 1 Diabetes
Published in: Diabetologia / Issue 5/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-021-05391-w

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Graphical abstract

Please log in to get access to this content

Other articles of this Issue 5/2021

Biphasic dynamics of beta cell mass in a mouse model of congenital hyperinsulinism: implications for type 2 diabetes

Saturated fatty acids entrap PDX1 in stress granules and impede islet beta cell function

A global perspective on the issue of access to insulin

Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study

Realising the long-term promise of insulin therapy: the DCCT/EDIC study

Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage